![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24497-24502, August 27, 1999
From the INSERM U344, Faculté de Médecine Necker, 156 rue de Vaugirard, 75730 Paris Cedex 15, France
| |
ABSTRACT |
|---|
|
|
|---|
Prolactin (PRL) has been shown to activate the
cytoplasmic tyrosine kinase Janus kinase 2 (Jak2) and the subsequent
recruitment of various signaling molecules including members of the
signal transducer and activator of transcription family of
transcription factors. Recently, an expanding family of
cytokine-inducible inhibitors of signaling has been identified that
initially included four members: suppressor of cytokine signaling
(SOCS)-1, SOCS-2, SOCS-3, and cytokine-inducible src homology domain 2 (SH-2) proteins. The present study analyzes the role of these members
in PRL signaling. Constitutive expression of SOCS-1 and SOCS-3
suppressed PRL-induced signal transducer and activator of transcription
5-dependent gene transcription, and Jak2 tyrosine kinase
activity was greatly reduced in the presence of SOCS-1 or SOCS-3.
SOCS-1 was shown to associate with Jak2, whereas SOCS-2 was associated
with the prolactin receptor. Co-transfection studies were conducted to
further analyze the interactions of SOCS proteins. SOCS-2 was shown to
suppress the inhibitory effect of SOCS-1 by restoring Jak2 kinase
activity but did not affect the inhibitory effect of SOCS-3 on PRL
signaling. Northern blot analysis revealed that SOCS-3 and
SOCS-1 genes were transiently expressed in response to PRL,
both in vivo and in vitro, whereas the
expression of SOCS-2 and CIS genes was still elevated 24 h after hormonal stimulation. We thus propose that the
early expressed SOCS genes (SOCS-1 and
SOCS-3) switch off PRL signaling and that the later
expressed SOCS-2 gene can restore the sensitivity of cells
to PRL, partly by suppressing the SOCS-1 inhibitory effect.
Prolactin (PRL)1 exerts
its effects via the PRL receptor (PRLR) and the activation of
intracellular signaling molecules through the Jak-STAT pathway (1).
Ligand binding leads to dimerization of the receptor and activation of
Jak2, which in turn phosphorylates the PRL receptor and the
transcription factor STAT5. However, less is known regarding how PRL
signal transduction is switched off. In addition to Jak2 and STAT5
induction, PRL receptor activation also results in the stimulation of
the protein tyrosine phosphatase SHP-2; however, in the case of the PRL
receptor, a positive role in signal transduction has been assigned (2).
Recently, a novel family of proteins capable of suppressing cytokine
signal transduction has been identified that function in a classic
negative feedback loop to regulate cytokine signaling (3-11).
Expression of suppressor of cytokine signaling (SOCS)-1 suppresses
interleukin 6-induced macrophage differentiation of murine myeloid
leukemia cell line M1 and interleukin 6-induced receptor
phosphorylation as well as STAT activation. SOCS-1 interacts with the
catalytic region of Jak kinases and suppresses their tyrosine kinase
activity and, as a result, the activation of STATs. Studies of mutated
or deleted SOCS-1 proteins reported that the N-terminal domain and the
SH-2 domain were required to inhibit leukemia-inhibitory factor signal transduction (12).
SOCS-1 and SOCS-3 have also been shown to block GH receptor signaling
(13) and interferon-mediated antiviral and anti-proliferative activities (14). SOCS-1 and CIS3 were shown to inhibit Il-6 and PRL
signaling (15, 16), but with different regulatory roles and different
potencies. However, the regulatory role of SOCS molecules is not
limited to the cytokine receptor superfamily because SOCS-2 interacts
both in vivo and in vitro with insulin-like growth factor I receptor, suggesting that SOCS proteins may play a more
general role in receptor signaling (17). Given the converging signaling
pathways between the cytokines and PRL, we have investigated the role
of the four initial members of the SOCS family (SOCS-1, SOCS-2, SOCS-3,
and CIS) in PRL signal transduction and shown that SOCS proteins have
dual effects with the ability to both inhibit and restore PRL signaling
through different mechanisms.
Reagents and Antibodies--
Ovine PRL was a gift from the
National Hormone and Pituitary/National Institute of Diabetes and
Digestive and Kidney Diseases program (Baltimore, MD). Anti-FLAG
monoclonal antibody M2 is a product of IBI-Kodak. The
anti-phosphotyrosine antibody ( Cells--
T-47D human mammary cancer cells were grown in
complete medium consisting of RPMI 1640 medium containing 10% fetal
calf serum. Cells were deprived of serum for a 24-h period before the
addition of human PRL (1 µg/ml) for different time periods.
Animals--
Livers were obtained immediately after death from
female 8-week-old C57BL/6 mice that had been injected intraperitoneally with ovine PRL (1 µg/g body weight) for different time periods.
Transient Transfection for LHRE-TK-Luciferase Assay--
293
cells were split into 6-well plates before being transiently
transfected using the calcium phosphate technique with 0.5 µg of
pCH110 ( Immunoprecipitation and Western Blotting--
Each 100-mm
culture dish of 293 cells was co-transfected with 1 µg of PRLR
cDNA, 0.5 µg of cDNA encoding the human tyrosine kinase Jak2,
and 4 µg of each form of SOCS-encoding plasmid. For co-expression
experiments, 1 µg of SOCS-1-encoding plasmid and 10 µg of
SOCS-2-encoding plasmid or 2 µg of SOCS-3-encoding plasmid and 20 µg of SOCS-2-encoding plasmid were co-transfected. Cells were
stimulated by oPRL (18 nM) for 15 min. Cells were
subsequently lysed as described previously, and the lysates were
incubated with anti-Jak2 antibody (1 µg/ml) or anti-FLAG antibody
(0.5 µg/ml) and collected using protein A-agarose or protein
G-agarose (18, 20). Immunoprecipitated proteins were separated by
SDS-polyacrylamide gel electrophoresis (7%); transferred onto
polyvinylidene difluoride transfer membrane (PolyscreenTM;
NEN Life Science Products); and immunodetected with appropriate antibodies to anti-Jak2 (Upstate Biotechnology, Inc.; 1:1,000), anti-phosphotyrosine (Upstate Biotechnology, Inc.; 1:10,000), anti-FLAG
(Kodak; 0.5 µg/ml), and anti-PRLR (monoclonal antibody 5; 1 µg/ml);
and visualized by ECF or ECL (Amersham Pharmacia Biotech). The
experiments were repeated four to seven times, and a representative
blot is shown in the figures.
RNA Preparation and Northern Blot Analysis--
The preparation
of RNA from cell cultures and liver samples was carried out according
to the acidic/phenol/chloroform method. Northern blot analysis was
performed essentially as described previously (21) using full-length
cDNA inserts encoding SOCS-1, SOCS-2, SOCS-3, or CIS that were
radiolabeled by random priming. The membranes were stripped in boiling
0.1% SDS and reprobed with the given probe. Three to four independent
experiments were performed, and a representative experiment is shown in
the figures.
Expression of SOCS Genes in Mammary and Hepatic Cells--
The
induction of SOCS-1, SOCS-2, SOCS-3, and CIS gene
expression in mouse liver and in T-47D mammary cells upon PRL
stimulation is shown in Fig. 1.
SOCS-3 and, to a lesser extent, SOCS-1 are transiently expressed in liver and mammary cells, whereas
SOCS-2 and CIS have somewhat different
kinetics of induction and are still elevated 24 h after
hormonal stimulation.
SOCS-1 and SOCS-3 Inhibit the Functional Activity of PRLR--
The
effect of the constitutive expression of SOCS genes on the response of
293 cells to PRL was investigated using the LHRE construct, for which
we obtained a maximal activation of 20.1 ± 0.8 (n = 6)-fold upon PRL stimulation when SOCS plasmids were not transfected.
Luciferase activity obtained in dose-response experiments has been
normalized to these maximal fold induction values and is expressed as a
percentage of these values (19). The constitutive expression of the
SOCS-1 gene at increasing concentrations led to inhibition of the
activation of transcriptional activity starting with very low doses of
transfected cDNA (25 ng/well) (Fig.
2).
SOCS-3 constitutive expression also led to the inability of the PRLR to
transmit the transcriptional response; however, this was achieved with
higher concentrations of transfected plasmid. Interestingly, expression
of SOCS-2 resulted in a partial inhibition in signaling (40%; the mean
was statistically different (p < 0.01, Fisher's test)
from 0 µg of SOCS-2 transfected plasmid), and this was obtained only
with low concentrations of transfected plasmid (25 ng/plate) (Fig. 2).
Lowering the concentration of transfected SOCS-2 to 1 ng/plate did not
further inhibit signaling (data not shown); higher concentrations
actually resulted in a restoration of the responsiveness of the LHRE
construct to PRL (Fig. 2). Constitutive expression of CIS
had no effect on the activation of gene
transcription by PRL.
Immunoblot analysis of 293 cell lysates that were immunoprecipitated
with Jak2 antibody revealed that upon constitutive expression of SOCS-1
or SOCS-3, PRL-induced tyrosine phosphorylation of Jak2 was greatly
reduced (Fig. 3). Constitutive expression of CIS or SOCS-2 plasmid did
not affect Jak2 tyrosine kinase activity (Fig. 3).
Interactions of SOCS Molecules in PRL Signaling--
To further
investigate the interactions of SOCS proteins in PRLR-mediated
activation of gene transcription, cDNAs encoding SOCS proteins were
co-transfected together with PRLR and the LHRE-TK-luciferase construct
in 293 cells. As shown in Fig.
4A, the constitutive expression of SOCS-1 and SOCS-2 at increasing concentrations resulted in the restoration of activation of transcriptional activity in a
dose-dependent manner. Western blot analysis indicates that the level of expression of SOCS-1 is not affected by SOCS-2
co-transfection (Fig. 4B). The same experiments conducted
with SOCS-3 and increasing concentrations of transfected SOCS-2 did not
show any restoration of PRL signaling (Fig. 4A), indicating
that the rescue of signal transduction by SOCS-2 was specific to
SOCS-1. Constitutive expression of CIS at increasing concentrations
also failed to modify the effects of SOCS-1, SOCS-2, and SOCS-3 on
PRL-induced transactivation of the LHRE-TK promoter (Fig.
5).
SOCS-1 Associates with Jak2, and SOCS-2 Associates with the
PRLR--
To determine which molecules associate with the different
SOCSs in PRLR signaling, we conducted an immunoblot analysis of 293 cell lysates immunoprecipitated with the anti-FLAG antibody and further
analyzed them by Western blotting using an anti-phosphotyrosine antibody, as indicated in Fig. 6. Upon
constitutive expression of SOCS-1, a major band of 130 kDa
co-immunoprecipitated with the anti-FLAG antibody and was identified as
Jak2 by immunoblotting with an antibody to Jak2. Although SOCS-1 was
shown in Fig. 3 to greatly reduce but not completely suppress tyrosine
phosphorylation of Jak2, the apparent level of tyrosine phosphorylation
of Jak2 in Fig. 6 can be attributed mainly to the use of the anti-FLAG antibody for immunoprecipitation, which co-immunoprecipitates tyrosine-phosphorylated Jak2 through its recruitment to SOCS-1. Upon
constitutive expression of SOCS-2, a major band of 92 kDa was
co-immunoprecipitated with the anti-FLAG antibody. The PRLR monoclonal
antibody revealed the 92-kDa protein, indicating that SOCS-2 associates
with the PRLR. The level of tyrosine phosphorylation of the PRLR
increased upon PRL stimulation because SOCS-2 did not inhibit Jak2
kinase activity. SOCS-3 constitutive expression did not reveal any
major, specific tyrosine-phosphorylated protein co-immunoprecipitating
with the anti-FLAG antibody (Fig. 6) and similarly for CIS constitutive
expression; no major, specific tyrosine-phosphorylated protein was
co-immunoprecipitated with the anti-FLAG antibody (data not shown). A
minor but consistent band of 130 kDa corresponding to Jak2 was observed
upon SOCS-3 constitutive expression.
Mechanism of SOCS-2-induced Restoration of PRL Signaling--
To
determine whether Jak2 kinase was involved in the restoration process,
cDNAs encoding Jak2, PRLR, SOCS-1, and SOCS-2 were co-transfected.
Immunoblot analysis of cell lysates immunoprecipitated with Jak2
antibody revealed that upon co-expression of SOCS-1 and SOCS-2,
PRL-induced tyrosine phosphorylation of Jak2, which had been shown to
be greatly reduced by SOCS-1 alone, was restored (Fig.
7). However, this was not the case when
SOCS-3 and SOCS-2 were co-expressed, in which case no detectable Jak2
activity was observed with or without PRL stimulation (Fig. 7), in
agreement with the absence of restoration of activation of gene
transcription under these conditions. Immunoblot analysis of cell
lysates immunoprecipitated with the anti-FLAG antibody is shown in Fig.
7 and indicates that the major tyrosine-phosphorylated band corresponds
to the 92-kDa PRLR and is induced by PRL, although a minor 130-kDa band
corresponding to Jak2 is present, and its tyrosine phosphorylation is
induced upon PRL stimulation, which is not the case when SOCS-1 alone is transfected (Fig. 6); thus, a large proportion of the PRLR is
associated with SOCS-2 during the restoration process. Also, the
apparent level of expression of SOCS-1 is not affected by SOCS-2
co-transfection (Fig. 7B) when compared with the
transfection of SOCS-1 alone (Fig. 6).
SOCS-2 Associates with Tyr-309 of the Intracellular Domain of the
PRLR--
To investigate the individual role of each tyrosine of the
cytoplasmic domain of the PRLR in SOCS-2 recruitment, cDNAs
encoding the natural and mutant forms of the PRLR including 9F in which all tyrosines were replaced by phenylalanines and individual
substitution of phenylalanine for tyrosines (8F-Ynnn) known to be
phosphorylated (18) were co-transfected with SOCS-2-encoding plasmid.
Lysates from PRL-stimulated cells were immunoprecipitated with
anti-FLAG antibody and further analyzed by Western blotting
using anti-phosphotyrosine antibody. As shown in Fig.
8, a major band of 92 kDa corresponding to the tyrosine-phosphorylated PRLR was co-immunoprecipitated with the
anti-FLAG antibody and was present only with wild type PRLR. None of
the mutants known to be docking sites for STAT5 and highly
tyrosine-phosphorylated (8F-Y580, 8F-Y479, and 8F-Y473) were associated
with SOCS-2. Although it was not detectable in the anti-phosphotyrosine
blot, the presence of mutant 8F-Y309 was detectable (but to a lesser
extent than the wild type) using the anti-PRLR antibody; indeed, this
mutant form is known to be weakly tyrosine-phosphorylated (18). These
results support the notion of an interaction between SOCS-2 and the
PRLR and suggest that Tyr-309 may represent a docking site for SOCS-2.
Understanding the mechanism by which PRL signaling is switched off
requires the identification of novel proteins capable of suppressing
PRL signal transduction. Recent reports have identified such proteins
for several cytokines; we now assess the role of these proteins in the
inhibition of PRL signal transduction pathways.
Both the SOCS-1 and SOCS-3 genes were transiently
expressed in mouse liver and T-47D mammary cells and shown to
completely inhibit the activation of gene transcription by PRL. SOCS-1
was more potent an inhibitor at low concentrations of protein than was
SOCS-3. This may correlate with the fact that lower levels of
SOCS-1 mRNA than SOCS-3 are induced in
hepatic cells in response to prolactin and GH (13). Accordingly, the
crucial role of SOCS-1 in postnatal growth and survival has been
demonstrated recently in mice lacking SOCS-1 (22).
Interaction of SOCS-1 with Jak2 markedly reduced its tyrosine kinase
activity upon PRL stimulation, supporting the observation that SOCS-1
interacts with the catalytic region of Jak kinases, thus inhibiting
their catalytic activity (5, 6) and, as a result, inhibiting the
activation of signaling intermediates such as STATs. SOCS-2 was a
partial inhibitor of signal transduction and, interestingly, when high
levels of the SOCS-2 gene were constitutively expressed, there was a
restoration of signaling by PRL without superinduction, as observed
after GH stimulation (13). Although the activity of SOCS-2 appears to
differ in regulating PRL and GH signal transduction, in both cases, the
enhanced response to cytokine with high levels of SOCS-2 suggests that
SOCS-2 itself may regulate the activity of endogenous suppressors such
as SOCS-1 or SOCS-3; indeed, co-transfection experiments using SOCS-1
and SOCS-2 indicated that SOCS-2 was able to suppress the inhibitory effect of SOCS-1 by restoring PRL signal transduction; however SOCS-2
did not suppress the inhibitory effect of SOCS-3. This is the first
demonstration of a dual effect of SOCS molecules by inhibiting and
restoring signaling.
Although CIS gene expression was induced by PRL, the
constitutive expression of this gene did not affect the activation of gene transcription by PRL. CIS has been shown to inhibit cytokine signal transduction by competing with STAT5 or other signaling molecules for docking sites on the receptor (3, 23, 24). Recently,
CIS3, also referred to as SOCS-3, and in addition SOCS-1 but not CIS1
have been shown also to inhibit PRL receptor-mediated STAT5 signaling
(16). The present experiments further indicate that CIS does not modify
the effects of SOCS-1, SOCS-2, and SOCS-3 on PRL signaling.
Although both SOCS-1 and SOCS-3 inhibited PRL-mediated activation of
gene transcription, several differences between the mechanisms of
action of SOCS-1 and SOCS-3 were observed: 1) SOCS-1 did associate with
Jak2 and inhibited its kinase activity, whereas SOCS-3 was weakly
associated with Jak2, 2) SOCS-1 was more potent than SOCS-3 in
suppressing PRL signaling, and 3) SOCS-2 appeared to restore PRL signal
transduction that had been inhibited by SOCS-1 but did not affect the
SOCS-3 inhibitory effect. Similarly, it has been reported that SOCS-3
has a lower affinity for Jak kinases than SOCS-1, and that SOCS-3 is a
weaker inhibitor of interleukin 6 signaling than SOCS-1 (15).
Furthermore, it has been shown recently that the inhibitions by SOCS-1
and SOCS-3 of interleukin 6 and leukemia-inhibitory factor-induced
macrophage differentiation of M1 cells involve distinct portions of the
Jak-STAT pathway, suggesting that the mechanisms of action of SOCS-1
and SOCS-3 in inhibiting signaling are quite different (12).
Interestingly, SOCS-2 was shown to be associated with the PRLR; as
such, SOCS-2 has been shown to associate with the insulin-like growth
factor I receptor, although the tyrosines involved in this interaction
are not known (17). The interaction of SOCS-2 with the PRLR most
probably involves Tyr-309 of the intracellular domain of the PRLR,
which is the closest phosphorylated tyrosine to Box1 of PRLR, the
region of association with Jak2 (25). The potent effect of SOCS-2 in
suppressing the inhibitory effect of SOCS-1, which itself associates
with Jak2, may result from the proximity of the regions of SOCS-2 and
SOCS-1 association, respectively, in the PRLR and in Jak2. Given the
fact that the SOCS-1 gene is expressed early as compared
with the SOCS-2 gene in mammary cells and hepatic cells in
response to PRL stimulation, a possible function of SOCS-2 would be to
restore PRL signaling and thus re-sensitize cells to PRL after the
initial inhibitory effect of SOCS-1. It will be interesting to test
whether this hypothesis can be extended to other members of the
expanding family of SOCS and CIS proteins and to other cytokines.
The SH-2 containing tyrosine phosphatases SHP-1 or SHP-2 do not appear
to be involved in the inhibition of PRL signaling (2, 26) in contrast
to signal transduction pathways activated by GH or other cytokines. The
SOCS proteins appear as major regulator of PRL signaling; the complex
interaction between the different SOCS molecules in PRL signaling will
be further clarified by generation of mice lacking one or multiple
members of this family.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
PY) and the anti-Jak2 antibody
(
Jak2) were purchased from Upstate Biotechnology, Inc.
-galactosidase expression vector from Pharmacia), 0.1 µg
of LHRE-TK-luciferase (a fusion gene carrying six copies of the LHRE
and the TK minimal promoter linked to the coding region of the
luciferase gene; LHRE is a STAT5 binding element of the
-casein
promoter), 0.05 µg of plasmid pRc/cmv containing PRLR cDNA, and
increasing concentrations (25-250 ng DNA) of FLAG epitope-tagged SOCS-1, SOCS-2, SOCS-3, or CIS (also referred as CIS1) in pEF-BOS expression vector (4). After 24 h of expression, the cells were
incubated in the absence of serum before hormone stimulation (18 nM oPRL for 24 h) using serum-free Dulbecco's
modified Eagle's medium/F-12 and then lysed, and luciferase and
-galactosidase activities were measured (18, 19). Aliquots of
lysates were analyzed by Western blot using anti-FLAG monoclonal
antibody M2, which confirmed that increasing the concentration of
transfected SOCS plasmids resulted in increased expression of SOCS proteins.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (47K):
[in a new window]
Fig. 1.
Northern blot analysis of SOCS gene
expression in mice liver in vivo and in T-47D cells
in vitro. Total RNA (10 µg/lane) prepared from
the livers of C57BL/6 mice (left panels) or T-47D cells
(right panels) that had been treated with PRL for different
time periods were hybridized with the indicated cDNA probes. The
integrity of the RNA samples and the efficiency of transfer of RNA
samples were monitored by ethidium bromide staining, and the expression
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is
included as a loading control. The exposure time is 24 h.

View larger version (13K):
[in a new window]
Fig. 2.
Effect of constitutive expression of
(A) SOCS-1 and SOCS-3 and (B) SOCS-2
and CIS on PRL-induced transactivation of the LHRE-TK promoter.
293 cells were transfected and assayed as described under
"Experimental Procedures." In these experiments, the results of
luciferase activity were assayed in cells transfected with several
ratios (1:2 to 5:1) of SOCS to PRLR cDNA. Dose-response curves are
expressed as a percentage of the control activity (in the absence of
co-transfected SOCS). 100% corresponds to a luciferase induction of
20.1-fold. Values are the means ± S.E. of four independent
experiments.

View larger version (36K):
[in a new window]
Fig. 3.
The ability of SOCS-1 and SOCS-3 to inhibit
tyrosine phosphorylation of Jak2. 293 cells expressing
PRLR, Jak2, and various SOCS constructs were incubated in the presence
(+) or absence (
) of 18 nM oPRL at 37 °C before lysis
and immunoprecipitation with
Jak2. Immunoprecipitated proteins were
Western blotted with
PY or
Jak2. The position of Jak2 (130 kDa)
is indicated. Molecular masses of the protein standards are indicated
on the left in kDa. Control experiments using 293 cells that
were not co-transfected with SOCS-encoding plasmids showed patterns
similar to cells transfected with CIS or SOCS-2 plasmids (data not
shown; Ref. 9).

View larger version (25K):
[in a new window]
Fig. 4.
Effect of constitutive co-expression of
SOCS-1 and SOCS-2 or SOCS-3 and SOCS-2 on PRL-induced transactivation
of the LHRE-TK promoter. A, 293 cells were transfected and
assayed as described under "Experimental Procedures." In these
experiments, the results of luciferase activity were assayed in cells
transfected without SOCS cDNA (0:0) or with a ratio of 1:1 or 2:1
of SOCS-1 or SOCS-3, respectively, to PRLR cDNA and several ratios
(1:0 to 1:10) of SOCS-1 or SOCS-3 to SOCS-2 cDNA. Dose-response
curves are expressed as a percentage of control activity (in the
absence of co-transfected SOCS). 100% corresponds to a luciferase
induction of 19.2-fold. Values are the means ± S.E. of four
independent experiments. B, aliquots of cell lysates
co-transfected with SOCS-1 and-SOCS2 were analyzed by Western blot
using the anti-FLAG M2 antibody.

View larger version (19K):
[in a new window]
Fig. 5.
Effect of constitutive co-expression of
SOCS-1, SOCS-2, SOCS-3, and CIS on PRL-induced transactivation of the
LHRE-TK promoter. 293 cells were transfected and assayed as
described under "Experimental Procedures." In these experiments,
the results of luciferase activity were assayed in cells transfected
without SOCS cDNA (0:0) or with a ratio of 1:1, 1:1, and 2:1 of
SOCS-1, SOCS-2, and SOCS-3, respectively, to PRLR cDNA and several
ratios (1:0 to 1:10) of SOCS to CIS cDNA. Dose-response curves are
expressed as a percentage of control activity (in the absence of
co-transfected SOCS). 100% corresponds to a luciferase induction of
17.8-fold. Values are the means ± S.E. of four independent
experiments.

View larger version (58K):
[in a new window]
Fig. 6.
Association of PRLR signaling molecules with
SOCS proteins. 293 cells expressing PRLR, Jak2, and various SOCS
constructs were incubated in the presence (+) or absence (
) of 18 nM oPRL at 37 °C before lysis and immunoprecipitation
with
FLAG. Lane U, cells that were not transfected with
SOCS plasmids. Lane V, immunoprecipitation with a control
antibody (monoclonal antibody 263). Immunoprecipitated proteins were
Western blotted with
PY,
Jak2,
FLAG, or
PRLR. The positions
of Jak2 (130 kDa) and PRLR (92 kDa) are indicated. Molecular masses of
the protein standards are indicated on the left in kDa.
Because SOCS-1 and SOCS-2 are migrating in the region of immunoglobulin
light chains, an enlargement of the blot is shown to better visualize
the SOCS-1 and SOCS-2 proteins.

View larger version (24K):
[in a new window]
Fig. 7.
The ability of SOCS-2 to restore tyrosine
phosphorylation of Jak2. 293 cells expressing PRLR,
Jak2, and various SOCS constructs were incubated in the presence (+) or
absence of (
) of 18 nM PRL at 37 °C for 15 min before
lysis and immunoprecipitation with
Jak2 (A) or
FLAG
(B). Immunoprecipitated proteins were Western blotted with
PY,
Jak2, or
PRLR. The positions of Jak2 (130 kDa), the PRLR
(92 kDa), and SOCS (20-24 kDa) are indicated. Molecular masses of the
protein standards are indicated on the left in kDa.
Lane U, cells that were not transfected with SOCS plasmids.
Lane V, immunoprecipitation with a control antibody
(monoclonal antibody 263).

View larger version (57K):
[in a new window]
Fig. 8.
The ability of wild type and mutated PRLR to
associate with SOCS-2 in response to PRL. 293 cells expressing
various forms of wild type (WT) or mutated PRLR and SOCS-2
were stimulated with 18 nM oPRL for 15 min at 37 °C.
Whole cell extracts were immunoprecipitated with anti-FLAG antibody and
Western blotted with
PY,
PRLR (7.5% SDS-polyacrylamide gel
electrophoresis), or
FLAG antibodies (15% SDS-polyacrylamide gel
electrophoresis). Molecular masses of the proteins standard are
indicated on the left in kDa. The arrows indicate
the migration of the proteins.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank D. Hilton and R. Starr for the gift of SOCS-pEF-BOS expression vectors and for reading and editing the manuscript. Ovine PRL was kindly provided by the National Hormone and Pituitary Program.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: INSERM U344,
Endocrinologie Moléculaire, Faculté de Médecine
Necker Enfants Malades, 156 rue de Vaugirard, 75730 Paris Cedex 15, France. Tel.: 33-1-40-61-53-10; Fax: 33-1-43-06-04-43; E-mail:
marc.edery@necker.fr.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: PRL, prolactin; PRLR, prolactin receptor; SOCS, suppressor of cytokine signaling; CIS, cytokine-inducible SH-2 protein; Jak2, Janus kinase 2; STAT, signal transducer and activator of transcription; LHRE, lactogenic hormone-responsive element; oPRL, ovine prolactin; GH, growth hormone; TK, thymidine kinase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bole-Feysot, C.,
Goffin, V.,
Edery, M.,
Binart, N.,
and Kelly, P. A.
(1998)
Endocr. Rev.
19,
225-268 |
| 2. | Ali, S., Chen, Z., Lebrun, J. J., Vogel, W., Kharitonenkov, A., Kelly, P. A., and Ullrich, A. (1996) EMBO J. 15, 135-142[Medline] [Order article via Infotrieve] |
| 3. | Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Hara, T., and Miyajima, A. (1995) EMBO J. 14, 2816-2826[Medline] [Order article via Infotrieve] |
| 4. | Starr, R., Willson, T. A., Viney, E. M., Murray, L. J., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., and Hilton, D. J. (1997) Nature 387, 917-921[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., Miyazaki, T., Leonor, N., Taniguchi, T., Fujita, T., Kanakura, Y., Komiya, S., and Yoshimura, A. (1997) Nature 387, 921-924[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., Akira, S., and Kishimoto, T. (1997) Nature 387, 924-929[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Ohya, K.,
Kajigaya, S.,
Yamashita, Y.,
Miyazato, A.,
Hatake, K.,
Miura, Y.,
Ikeda, U.,
Shimada, K.,
Ozawa, K.,
and Mano, H.
(1997)
J. Biol. Chem.
272,
27178-27182 |
| 8. | Bjorbaek, C., Elmquist, J. K., Frantz, J. D., Shoelson, S. E., and Flier, J. S. (1998) Mol. Cell 1, 619-625[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Starr, R., and Hilton, D. J. (1998) Int. J. Biochem. Cell Biol. 30, 1081-1085[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Narazaki, M.,
Fujimoto, M.,
Matsumoto, T.,
Morita, Y.,
Saito, H.,
Kajita, T.,
Yoshizaki, K.,
Naka, T.,
and Kishimoto, T.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13130-13134 |
| 11. | Yoshimura, A. (1998) Leukemia (Baltimore) 12, 1851-1857[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Nicholson, S. E., Willson, T. A., Farley, A., Starr, R., Zhang, J. G., Baca, M., Alexander, W. S., Metcalf, D., Hilton, D. J., and Nicola, N. A. (1999) EMBO J. 18, 375-385[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Adams, T. E.,
Hansen, J. A.,
Starr, R.,
Nicola, N. A.,
Hilton, D. J.,
and Billestrup, N.
(1998)
J. Biol. Chem.
273,
1285-1287 |
| 14. |
Song, M. M.,
and Shuai, K.
(1998)
J. Biol. Chem.
273,
35056-35062 |
| 15. | Suzuki, R., Sakamoto, H., Yasukawa, H., Masuhara, M., Wakioka, T., Sasaki, A., Yuge, K., Komiya, S., Inoue, A., and Yoshimura, A. (1998) Oncogene 17, 2271-2278[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Helman, D., Sandowski, Y., Cohen, Y., Matsumoto, A., Yoshimura, A., Merchav, S., and Gertler, A. (1998) FEBS Lett. 441, 287-291[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Dey, B. R.,
Spence, S. L.,
Nissley, P.,
and Furlanetto, R. W.
(1998)
J. Biol. Chem.
273,
24095-24101 |
| 18. |
Pezet, A.,
Ferrag, F.,
Kelly, P. A.,
and Edery, M.
(1997)
J. Biol. Chem.
272,
25043-25050 |
| 19. |
Goffin, V.,
Kinet, S.,
Ferrag, F.,
Binart, N.,
Martial, J. A.,
and Kelly, P. A.
(1996)
J. Biol. Chem.
271,
16573-16579 |
| 20. |
Berlanga, J. J.,
Gualillo, O.,
Buteau, H.,
Applanat, M.,
Kelly, P. A.,
and Edery, M.
(1997)
J. Biol. Chem.
272,
2050-2052 |
| 21. |
Martini, J.-F.,
Pezet, A.,
Guezennec, C. Y.,
Edery, M.,
Postel-Vinay, M.-C.,
and Kelly, P. A.
(1997)
J. Biol. Chem.
272,
18951-18958 |
| 22. |
Starr, R.,
Metcalf, D.,
Elefanty, A. G.,
Brysha, M.,
Willson, T. A.,
Nicola, N. A.,
Hilton, D. J.,
and Alexander, W. S.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
14395-14399 |
| 23. |
Matsumoto, A.,
Masuhara, M.,
Mitsui, K.,
Yokouchi, M.,
Ohtsubo, M.,
Misawa, H.,
Miyajima, A.,
and Yoshimura, A.
(1997)
Blood
89,
3148-3154 |
| 24. | Yoshimura, A. (1998) Cytokine Growth Factor Rev. 9, 197-204 [CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Pezet, A., Buteau, H., Kelly, P. A., and Edery, M. (1997) Mol. Cell. Endocrinol. 129, 199-208[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Berchtold, S.,
Volarevic, S.,
Moriggl, R.,
Mercep, M.,
and Groner, B.
(1998)
Mol. Endocrinol.
12,
556-567 |
This article has been cited by other articles:
![]() |
J. L. Barclay, S. T. Anderson, M. J. Waters, and J. D. Curlewis Characterization of the SOCS3 Promoter Response to Prostaglandin E2 in T47D Cells Mol. Endocrinol., October 1, 2007; 21(10): 2516 - 2528. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Piessevaux, D. Lavens, T. Montoye, J. Wauman, D. Catteeuw, J. Vandekerckhove, D. Belsham, F. Peelman, and J. Tavernier Functional Cross-modulation between SOCS Proteins Can Stimulate Cytokine Signaling J. Biol. Chem., November 3, 2006; 281(44): 32953 - 32966. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Anderson, P. Beijer, A. S. Bang, M. A. Fenwick, S. J. Bunn, and D. R. Grattan Suppression of Prolactin-Induced Signal Transducer and Activator of Transcription 5b Signaling and Induction of Suppressors of Cytokine Signaling Messenger Ribonucleic Acid in the Hypothalamic Arcuate Nucleus of the Rat during Late Pregnancy and Lactation Endocrinology, October 1, 2006; 147(10): 4996 - 5005. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Lavens, T. Montoye, J. Piessevaux, L. Zabeau, J. Vandekerckhove, K. Gevaert, W. Becker, S. Eyckerman, and J. Tavernier A complex interaction pattern of CIS and SOCS2 with the leptin receptor J. Cell Sci., June 1, 2006; 119(11): 2214 - 2224. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gentili, M. J. Waters, and I. C. McMillen Differential regulation of suppressor of cytokine signaling-3 in the liver and adipose tissue of the sheep fetus in late gestation Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2006; 290(4): R1044 - R1051. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Anderson, J. L. Barclay, K. J. Fanning, D. H. L. Kusters, M. J. Waters, and J. D. Curlewis Mechanisms Underlying the Diminished Sensitivity to Prolactin Negative Feedback during Lactation: Reduced STAT5 Signaling and Up-Regulation of Cytokine-Inducible SH2 Domain-Containing Protein (CIS) Expression in Tuberoinfundibular Dopaminergic Neurons Endocrinology, March 1, 2006; 147(3): 1195 - 1202. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ben-Zvi, A. Yayon, A. Gertler, and E. Monsonego-Ornan Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling J. Cell Sci., January 15, 2006; 119(2): 380 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Tannahill, J. Elliott, A. C. Barry, L. Hibbert, N. A. Cacalano, and J. A. Johnston SOCS2 Can Enhance Interleukin-2 (IL-2) and IL-3 Signaling by Accelerating SOCS3 Degradation Mol. Cell. Biol., October 15, 2005; 25(20): 9115 - 9126. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Lindberg, S G Ronn, D Tornehave, H Richter, J A Hansen, J Romer, M Jackerott, and N Billestrup Regulation of pancreatic {beta}-cell mass and proliferation by SOCS-3 J. Mol. Endocrinol., October 1, 2005; 35(2): 231 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Miquet, A. I. Sotelo, A. Bartke, and D. Turyn Desensitization of the JAK2/STAT5 GH signaling pathway associated with increased CIS protein content in liver of pregnant mice Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E600 - E607. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Blumenstein, J A Keelan, J M Bowen-Shauver, and M D Mitchell Suppressors of cytokine signaling proteins in human preterm placental tissues J. Mol. Endocrinol., August 1, 2005; 35(1): 165 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rico-Bautista, C. J. Greenhalgh, P. Tollet-Egnell, D. J. Hilton, W. S. Alexander, G. Norstedt, and A. Flores-Morales Suppressor of Cytokine Signaling-2 Deficiency Induces Molecular and Metabolic Changes that Partially Overlap with Growth Hormone-Dependent Effects Mol. Endocrinol., March 1, 2005; 19(3): 781 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Brelje, L. E. Stout, N. V. Bhagroo, and R. L. Sorenson Distinctive Roles for Prolactin and Growth Hormone in the Activation of Signal Transducer and Activator of Transcription 5 in Pancreatic Islets of Langerhans Endocrinology, September 1, 2004; 145(9): 4162 - 4175. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-J. M. van de Geijn, J. Gits, and I. P. Touw Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling J. Leukoc. Biol., July 1, 2004; 76(1): 237 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Johnston Are SOCS suppressors, regulators, and degraders? J. Leukoc. Biol., May 1, 2004; 75(5): 743 - 748. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Okamura, N. Iwata, A. Nagata, A. Tamekane, M. Shimoyama, H. Gomyo, K. Yakushijin, N. Urahama, M. Hamaguchi, C. Fukui, et al. Involvement of casein kinase I{epsilon} in cytokine-induced granulocytic differentiation Blood, April 15, 2004; 103(8): 2997 - 3004. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ali, Z. Nouhi, N. Chughtai, and S. Ali SHP-2 Regulates SOCS-1-mediated Janus Kinase-2 Ubiquitination/Degradation Downstream of the Prolactin Receptor J. Biol. Chem., December 26, 2003; 278(52): 52021 - 52031. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C. Calegari, R. M. N. Bezerra, M. A. Torsoni, A. S. Torsoni, K. G. Franchini, M. J. A. Saad, and L. A. Velloso Suppressor of Cytokine Signaling 3 Is Induced by Angiotensin II in Heart and Isolated Cardiomyocytes, and Participates in Desensitization Endocrinology, October 1, 2003; 144(10): 4586 - 4596. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Olayioye, M. A. Guthridge, F. C. Stomski, A. F. Lopez, J. E. Visvader, and G. J. Lindeman Threonine 391 Phosphorylation of the Human Prolactin Receptor Mediates a Novel Interaction with 14-3-3 Proteins J. Biol. Chem., August 29, 2003; 278(35): 32929 - 32935. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler The Role of Prolactin in Mammary Carcinoma Endocr. Rev., February 1, 2003; 24(1): 1 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Giordanetto and R. T. Kroemer A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1) Protein Eng. Des. Sel., February 1, 2003; 16(2): 115 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Allan, E. Tonner, M. C. Barber, M. T. Travers, J. H. Shand, R. G. Vernon, P. A. Kelly, N. Binart, and D. J. Flint Growth Hormone, Acting in Part through the Insulin-Like Growth Factor Axis, Rescues Developmental, But Not Metabolic, Activity in the Mammary Gland of Mice Expressing a Single Allele of the Prolactin Receptor Endocrinology, November 1, 2002; 143(11): 4310 - 4319. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Greenhalgh, D. Metcalf, A. L. Thaus, J. E. Corbin, R. Uren, P. O. Morgan, L. J. Fabri, J.-G. Zhang, H. M. Martin, T. A. Willson, et al. Biological Evidence That SOCS-2 Can Act Either as an Enhancer or Suppressor of Growth Hormone Signaling J. Biol. Chem., October 18, 2002; 277(43): 40181 - 40184. [Abstract] [Full Text] [PDF] |
||||
![]() |
|